Company: PCRX
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001104659-25-041219
Chunk: 36

Company: Pacira BioSciences, Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 36
---
 Froimson | ​ |

44 | investor.pacira.com

TABLE OF CONTENTS

| ​ | ​ | EXECUTIVEOFFICERS | ​ |

| ​ | ​                           | ​ | ​ | ​                                   | ​ | ​ | ​            | ​ | ​ |                   | ​ | ​ | ​                     | ​ | ​ | ​                         | ​ | ​ | ​                                           | ​ | ​ | ​                     | ​ | ​ | ​          | ​ | ​ | ​          | ​ |
| ​ | 2025PROXY STATEMENT SUMMARY | ​ | ​ | CORPORATEGOVERNANCEAND BOARDMATTERS | ​ | ​ | AUDITMATTERS | ​ | ​ | EXECUTIVEOFFICERS | ​ | ​ | EXECUTIVECOMPENSATION | ​ | ​ | STOCKOWNERSHIPINFORMATION | ​ | ​ | INFORMATIONABOUT THEANNUALMEETING ANDVOTING | ​ | ​ | ADDITIONALINFORMATION | ​ | ​ | APPENDIX A | ​ | ​ | APPENDIX B | ​ |

TABLE OF CONTENTS EXECUTIVE OFFICERS

| ​ | ​ | Executive Officers | ​ |

The following sets forth certain information with respect to the executive officers of the Company as of April 17, 2025.

| Name                   | ​ | ​ | Age | ​ | ​ | Position                                   | ​ |
| Frank D. Lee           | ​ | ​ |  57 | ​ | ​ | Chief Executive Officer                    | ​ |
| Shawn Cross            | ​ | ​ |  57 | ​ | ​ | Chief Financial Officer                    | ​ |
| Kristen Williams, Esq. | ​ | ​ |  51 | ​ | ​ | Chief Administrative Officer and Secretary | ​ |
| Jonathan Slonin, M.D.  | ​ | ​ |  50 | ​ | ​ | Chief Medical Officer                      | ​ |
| Brendan Teehan         | ​ | ​ |  56 | ​ | ​ | Chief Commercial Officer                   | ​ |

| ​ | AGE:57                                                                                                                                                                                                                                                                                                                                                      
 Chief Executive Officersince January 2024                                                                                                                                                                                                                                                                                                                   | ​ | ​ | FRANK D. LEE                                                                                                                  | ​ | ​ | DIRECTORsince January 2024 | ​ |
| ​ | KEY EXPERIENCE AND QUALIFICATIONS                                                                                                                                                                                                                                                                                                                           
 Mr. Lee brings nearly three decades of global experience and a strong track record of product development and commercial success across both small biotech and large pharmaceutical organizations. His focus on